| Full text | |
| Author(s): |
Lúcio Omar Carmignani
[1]
;
Adriana Orcesi Pedro
[2]
;
Lúcia Helena Simões da Costa-Paiva
[3]
;
Aarão Mendes Pinto-Neto
[4]
Total Authors: 4
|
| Affiliation: | [1] Universidade Estadual de Campinas. Department of Obstetrics and Gynecology - Brasil
[2] Universidade Estadual de Campinas. Department of Obstetrics and Gynecology - Brasil
[3] Universidade Estadual de Campinas. Department of Obstetrics and Gynecology - Brasil
[4] Universidade Estadual de Campinas. Department of Obstetrics and Gynecology - Brasil
Total Affiliations: 4
|
| Document type: | Journal article |
| Source: | Revista Brasileira de Ginecologia e Obstetrícia; v. 36, n. 6, p. 251-258, 2014-06-00. |
| Abstract | |
PURPOSE: To assess the effects of a soy dietary supplement on the main biomarkers of cardiovascular health in postmenopausal women compared with the effects of low-dose hormone therapy (HT) and placebo. METHODS: Double-blind, randomized and controlled intention-to-treat trial. Sixty healthy postmenopausal women, aged 40-60 years, 4.1 years mean time since menopause were recruited and randomly assigned to 3 groups: a soy dietary supplement group (isoflavone 90mg), a low-dose HT group (estradiol 1 mg plus noretisterone 0.5 mg) and a placebo group. Lipid profile, glucose level, body mass index, blood pressure and abdominal/hip ratio were evaluated in all the participants at baseline and after 16 weeks. Statistical analyses were performed using the χ2 test, Fisher's exact test, Kruskal-Wallis non-parametric test, analysis of variance (ANOVA), paired Student's t-test and Wilcoxon test. RESULTS: After a 16-week intervention period, total cholesterol decreased 11.3% and LDL-cholesterol decreased 18.6% in the HT group, but both did not change in the soy dietary supplement and placebo groups. Values for triglycerides, HDL-cholesterol, glucose level, body mass index, blood pressure and abdominal/hip ratio did not change over time in any of the three groups. CONCLUSION: The use of dietary soy supplement did not show any significant favorable effect on cardiovascular health biomarkers compared with HT. Clinical Trial Registry: The trial is registered at the Brazilian Clinical Trials Registry (Registro Brasileiro de Ensaios Clínicos - ReBEC), number RBR-76mm75. (AU) | |